Table 1.
FDA Approved targeted therapies for metastatic colorectal cancer.
| Targeted Therapy | Trade Name | Year of Approval | Pathway |
|---|---|---|---|
| Cetuximab | Erbitux | 2004 | EGFR inhibitor |
| Panitumumab | Vectibix | 2006 | EGFR inhibitor |
| Bevacizumab | Avastin | 2004 | VEGF inhibitor |
| Ramucirumab | Cyramza | 2015 | VEGF inhibitor |
| Aflibercept | Zaltrap | 2012 | VEGF inhibitor |
| Fruquintinib | Fruzaqla | 2023 | VEGF inhibitor |
| Encorafenib | Braftovi | 2020 | BRAF inhibitor |
| Trastuzumab | Herceptin | 2022 | HER2 inhibitor |
| Pertuzumab | Perjeta | 2022 | HER2 inhibitor |
| Tucatinib | Tukysa | 2023 | HER2 inhibitor |
| Larotrectinib | Vitrakvi | 2018 | NTRK inhibitor |
| Entrectinib | Rozlytrek | 2019 | NTRK inhibitor |
| Regorafenib | Stivarga | 2012 | Multi-kinase inhibitor |
| Nivolumab | Opdivo | 2017 | PD-1 inhibitor |
| Pembrolizumab | Keytruda | 2017 | PD-1 inhibitor |
| Ipilimumab | Yervoy | 2018 | CTLA-4 inhibitor |